Antimicrobial (antibiotic) Resistance – the drugs won’t work !

Antimicrobial resistance (AMR) poses a significant global threat of far-reaching proportions. It is estimated that drug resistant infections contribute to nearly 5 million deaths every year and predicted to increase to over 10 million deaths every year.  WHO has declared that AMR is one of the top 10 global public health threats facing humanity.

(The worldwide total deaths from COVID is now just over 6 million and we all know how frightening it was before the vaccine was developed)

 

AMR occurs when bacteria, viruses, fungi and parasites change over time and no longer respond to medicines making infections harder to treat and increasing the risk of disease spread, severe illness and death. As a result, the medicines become ineffective and infections persist in the body, increasing the risk of spread to others. Microorganisms that develop antimicrobial resistance are sometimes referred to as “superbugs”. Without effective antimicrobials, the success of modern medicine in treating infections, including during major surgery and cancer chemotherapy, would be at increased risk. Chronic infections if left untreated could result in tissue damage, amputation, longer stays in hospitals, surgical interventions, or increased possibility of mortality. Patients who are infected with drug-resistant infections are more likely to develop complications and are up to three times more likely to die from the infection. Non-healing wounds in particular, are characterised by complex and mixed bacterial populations, often involving antibiotic-resistant bacteria as well as phenotypically tolerant bacteria in biofilm form. The biofilm factor is clearly of considerable clinical importance: it protects bacteria from antimicrobial agents leading to persistent and difficult to treat chronic infections, and it exacerbates the spread of antibiotic resistance. Surgical Site Infections are also linked to anti-microbial resistance.

 

SteriPlas cold plasma technology kills bacteria by a physical mode of action and bacteria are therefore unlikely to develop primary or secondary resistance, which we have documented from our clinical studies. SteriPlas cold plasma also kills antibiotic resistant bacteria (e.g. MRSA) and kills bacteria encased in biofilm which are typically up to 1000 times more resistant to antibiotics. SteriPlas has proven clinical efficacy in treating wound infections,  diabetic foot infections and surgical site infections in all clinical studies, all with the bonus of no side effects reported. 

 

SteriPlas cold plasma can be used to treat topical infections reserving antibiotics for severe systemic infections.

 

References

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02724-0/fulltext

https://www.worldometers.info/coronavirus/

https://www.who.int/health-topics/antimicrobial-resistance

https://healthfirsteurope.eu/wp-content/uploads/2020/11/A3A4-48pp-Booklet-Spreads-1.pdf

Bowler, P., Murphy, C. & Wolcott, R. Biofilm exacerbates antibiotic resistance: Is this a current oversight in antimicrobial stewardship?. Antimicrob Resist Infect Control 9, 162 (2020).


EUMS-ISMCS 2022

 

We are overwhelmed by all the positive interactions we've had at the EUMS-ISMCS 2022 conference. Lots of you have taken a huge interest into our Cold Plasma SteriPlas medical device and its strong efficacy with LVAD infections. It's great to have seen regular faces as well as meeting new.

We hope you also got to see Dr Heinrich Rotering's presentation during the conference, "Treatment of Biofilm-Infested Implants - A Tissue Saving Approach". His great presentation elaborates the key benefits of using the SteriPlas for Sternal wound infections and LVAD infections.

Contact us for more info on info@adtecplasma.com


LVAD - Heidelberg publication 2021

 

Congratulations to Dr Kremer and the Cardiology Team at The University Hospital Heidelberg for their new publication, “Follow-Up after Cold Atmospheric Argon Plasma for Wound Management of Driveline Infections - A Promising Strategy”. This publication features the use of our Adtec SteriPlas medical device for the treatment of driveline infections (DLI). The results demonstrate how the safety, reliability and painless treatment from the Adtec SteriPlas can significantly reduce the wound and infection around the DLI, with the opportunity for sustainable freedom from DLI.


Deep Sternum Surgical Site Infections (DSSIs)

 

Deep sternal surgical site infections (DSSIs) are a still a severe complication after cardiac surgery. The mortality estimated range is between 15%-40% of all cases. In addition to the significantly extended hospitalization, there is a significant cost burden with a calculated cost of € 36,000 for a single DSSI case.

The use of the Adtec SteriPlas for these complicated conditions has been actively documented as better managing the chronic infections, reducing hospitalization times and cost but more importantly it has shown to decrease the mortality rate. Our medical device has been praised as a tissue and life saving medical device.


Herz medizin 2021

We look forward to supporting Dr Heinrich Rotering’s presentation, “Avoiding sternal wire removal in early onset of sternal site infection - Two years experience with an optimized treatment concept using cold atmospheric plasma“ at the Annual scientific meeting of the German Society for Thoracic, Cardiac and Vascular Surgery. His presentation will discuss the strong benefits of using the Adtec SteriPlas for complicated sternal wound infections in cardiac patients.

 

The conference will be held virtually between 26-28 February: https://www.dgthg.de/de/jahrestagung


Adtec SteriPlas for the treatment of deep sternal wound infections and infected drivelines

The Adtec SteriPlas has already been well documented for the treatment of deep sternal wound infections and infected drivelines. Separate studies from two leading hospitals in Germany (University Hospital Munster and University Hospital Heidelberg) have recorded the strong efficacy of our cold plasma treatment on these problematic conditions. Due to the original difficulty of managing these chronic infections using standard therapies along with the high rate of morbidity and mortality, it is no wonder why the Adtec SteriPlas has been chosen as the preferred treatment method.

 

You can read more about its story in the latest addition of the Chirurgische Allgemeine magazine: eSD_AdTecPlasma

 


SteriPlas cold plasma successful at killing multi-resistant bacteria

Our animation video shows how bacteria are easily destroyed using our patented cold plasma technology. The components of cold plasma work collectively to target bacteria and physically rupture the structure, allowing micropores to be created which gains access to the microbial DNA to be destroyed. This effectively kills bacteria, even if they are protected within biofilm.

 

Learn more about our clinical evidence by visiting our webpage www.adtechealthcare.com or send us an email at info@adtecplasma.com

Click the link below to access the animation video:

Animation video to show how the SteriPlas can successfully kill multi-resistant bacteria